21 февр. 2024 г. · CASGEVY indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso occlusive crises (VOCs).

8 дек. 2023 г. · The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years ...

CASGEVY is indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). 2 DOSAGE AND ...

16 янв. 2024 г. · Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia · Low levels ...

You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of CASGEVY. Talk to your healthcare provider about ...

17 янв. 2024 г. · Casgevy was approved for use in the treatment of transfusion-dependent beta thalassemia on January 16, 2024. Development timeline for Casgevy ...

16 янв. 2024 г. · The major risk of treatment with CASGEVY is the potential for off-target, unintended genome editing by CRISPR/Cas9. The review team recommends ...

16 янв. 2024 г. · The US Food and Drug Administration has approved a second use for the first CRISPR-based medicine, Casgevy, which was approved in December to treat sickle cell ...

8 дек. 2023 г. · U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 genome-edited cell therapy ...

Aside from FDA approval, CASGEVY™ has gained approval for transfusion-dependent thalassaemia by the UK's Medicines & Healthcare products ...